Glenn Heller, PhD

Attending Biostatistician

Glenn Heller, PhD

Office Phone



New York University

Current Research Interests

Dr. Heller’s current research interests include the design and analysis of phase 2 clinical trials, the analysis of survival data, and the investigation of predictive accuracy measures. For the analysis of phase 2 studies, he has developed a test statistic that adjusts for patient risk when the patient population is heterogeneous. This approach is applicable in targeted therapy trials, where multiple patient populations are treated under a single protocol. In survival analysis, he has developed a measure of predictive accuracy, based on the concept of explained randomness.  This metric, applied to risk models with survival data, is used to determine the adequacy of a risk classification model for clinical decision making. In addition, he is developing statistical methods to evaluate the improvement in risk classification measures due to the inclusion of new biomarkers. The statistical methods will provide a metric to decide whether a change in patient risk, due to the inclusion of new biomarkers into the risk model, is random variation or a true improvement in the accuracy of a risk classification model. Finally, Dr. Heller is involved in the design and analysis of laboratory and clinical studies emanating from the Departments of Medicine, Pediatrics, and Surgery.


Selected peer-reviewed publications:

  1. Heller G, Seshan VE, Moskowitz CS, Gonen M. Inference for the difference in the area under the ROC curve derived from nested binary regression models. Biostatistics. 2017. 18: 260-274.
  2. Heller G, Fizazi K, McCormack RT, Molina A, MacLean D, Webb IJ, Saad F, de Bono JS, Scher HI. The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population. Clinical Cancer Research. 2017. 23: 1967-1973.
  3. Heller G, Mo X. Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Analysis. 2016. 22: 263-279.
  4. Heller G. A measure of explained risk in the proportional hazards model. Biostatistics. 2012. 13: 315-25.
  5. Heller G. Proportional hazards regression with interval censored data using an inverse probability weight. Lifetime Data Analysis. 2011. 17: 373-85.

Visit PubMed for a full listing of Glenn Heller’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

My Pages


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Glenn Heller discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at

View all disclosures